Maura Gillison
University of Texas MD Anderson Cancer Center

Last Updated On 1/24/2025 4:09:39 PM
This is a disclosure report of the user financial relationships with for-profit health care companies.
All relationships are considered compensated unless otherwise noted. Relationships are self-held unless otherwise noted.

Employment
No Relationships to Disclose

Leadership
No Relationships to Disclose

Stock and Other Ownership Interests
No Relationships to Disclose

Honoraria
No Relationships to Disclose

Consulting or Advisory Role
Company: Bristol-Myers Squibb
Recipient: You
Company: Merck
Recipient: You
Company: EMD Serono
Recipient: You
Company: BioNTech
Recipient: You
Company: Shattuck
Recipient: You
Company: Bayer
Recipient: You
Company: Debiopharm Group
Recipient: You
Company: Ipsen
Recipient: You
Company: Gilead Sciences
Recipient: You
Company: Bicara Therapeutics
Recipient: You
Company: BioNTech AG
Recipient: You
Company: Nektar
Recipient: You
Company: Istari
Recipient: You
Company: LLX Solutions
Recipient: You
Company: OncLive
Recipient: You
Company: Seagen
Recipient: You
Company: Kura
Recipient: You
Company: Mirati
Recipient: You
Company: Eisai
Recipient: You
Company: Exelixis
Recipient: You
Company: ITeos Therapeutics
Recipient: You
Company: Caladrius Biosciences
Recipient: You
Company: Coherus Biosciences
Recipient: You
Company: Surface
Recipient: You
Company: Merus
Recipient: You
Company: Adaptimmune
Recipient: You
Company: END Merck
Recipient: You
Company: Bristol-Myers Squibb/Roche
Recipient: You
Company: BioNTech SE
Recipient: You
Company: Journal of Clinical Oncology
Recipient: You
Company: Axiom Biotechnologies
Recipient: You
Company: Aptitude Health
Recipient: You
Company: EMD Serono
Recipient: You
Company: Bicara Therapeutics
Recipient: You
Company: Guidepoint Global
Recipient: You
Company: Coherus Biosciences
Recipient: You
Company: LLX Solutions
Recipient: You
Company: Abbvie
Recipient: You
Company: Pfizer
Recipient: You
Company: Brightly Network
Recipient: You
Company: Boxer Capital
Recipient: You
Company: Merus
Recipient: You
Company: EMD Serono
Recipient: You
Company: Takeda
Recipient: You
Company: Suzhou Liangyihui Network Technology
Recipient: You
Company: Sensei Biotherapeutics
Recipient: You

Speakers' Bureau
No Relationships to Disclose

Research Funding
Company: Bristol-Myers Squibb
Recipient: Your Institution
Company: Genocea Biosciences
Recipient: Your Institution
Company: Cullinan
Recipient: Your Institution
Company: Genentech
Recipient: Your Institution
Company: Agenus
Recipient: Your Institution
Company: Kura
Recipient: Your Institution
Company: Seagen
Recipient: Your Institution
Company: Abbvie
Recipient: Your Institution
Company: BioNTech SE
Recipient: Your Institution
Company: NRG Oncology
Recipient: Your Institution
Company: INVAX
Recipient: Your Institution
Company: Merus
Recipient: Your Institution
Company: Gilead Sciences
Recipient: Your Institution
Company: Merck
Recipient: Your Institution
Company: Roche
Recipient: Your Institution

Patents, Royalties, Other Intellectual Property
Please describe: PCT/US2022/023911 pending Board of Regents, The University of Texas System
Recipient: You

Expert Testimony
No Relationships to Disclose

Travel, Accommodations, Expenses
No Relationships to Disclose

Other Relationship
No Relationships to Disclose

(OPTIONAL) Uncompensated Relationships
No Relationships to Disclose

(OPTIONAL) Open Payments Link
No Relationships to Disclose